The signal holds, but the second week closes weak
Gilead gains 0.7% as sellers dominate the last session ahead of earnings
The signal holds, but the second week closes weak
Our view last week
Gilead Sciences shares closed the week down 3.7%, slipping back toward the double bottom in the 122 area after the past weeks' rebound. Buyer dominance is fading and sellers ruled the last bar: the first confirmation week of the fresh buy signal closes negative. Our technical analysis also flags earnings, due this very week.
This week's summary
Gilead gains 0.7% on the week but stays pinned against its 20- and 50-day moving averages, in the 131 area, with earnings due August 4th. The last session saw sellers clearly dominate volume even as price edged higher — a divergence worth watching. The buy signal fired two weeks ago, and the second confirmation week closes weak: the model suggests exiting the position.
IQS Phase
62
ordinary
Signal Strength
47
medium · weak
Sizing
REDUCED
Ranking
#73 / 120
US stocks in progress
Trade P&L %
-3.03%
from signal to date, no stop loss
Rank position
ranks 73rd among the 120 Longs already running for US stocks in our ranking, with a signal strength of 47 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -0.01% · monthly +1.89%
GILD belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content